Tscan Therapeutics Inc (TCRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.31 (-6.54%), Market cap $0.07B, 52-week low–high $0.90 ~ $2.52.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the compan
Financial statements, price targets, institutional (13F) holdings and related news for Tscan Therapeutics Inc are updated in real time on BlackAll Trade.
Tscan Therapeutics Inc trades at $0.31 (-6.54%). Real-time quotes and charts are available on BlackAll Trade.
Tscan Therapeutics Inc has a market cap of about $0.07B.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The compa